oral glp-1 agonist approved New Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity The GLP-1 Revolution Continues

Semaglutide (Wegovy) and tirzepatide (Zepbound) have demonstrated significant average weight loss14.9% and 20.9% of body weight at approximately one year, respectively

Application Insights The type 2 diabetes management segment accounted for the largest market share in 2025

J Biochem Mol Toxicol

Results Compared with initiation of SGLT-2 inhibitors, initiation of GLP-1 receptor agonists was associated with reduced risk of disorders related to alcohol use (hazard ratio 0.82 (95% confidence interval (CI) 0.78 to 0.85)

doi: 10.1007/s00109-004-0552-1

In the REWIND study and AWARD5 study, dulaglutide consistently improved BP and lipid levels in patients [23, 38]